Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 13 May 24 424B5 Prospectus supplement for primary offering
- 4 Mar 24 424B5 Prospectus supplement for primary offering
- 24 May 22 424B3 Prospectus supplement
- 1 Mar 22 424B5 Prospectus supplement for primary offering
- 26 Jul 21 424B5 Prospectus supplement for primary offering
- 22 Jul 21 FWP Free writing prospectus
- 22 Jul 21 FWP Free writing prospectus
- 22 Jul 21 424B5 Prospectus supplement for primary offering
- 4 Jun 21 424B3 Prospectus supplement
- 4 Jun 21 424B3 Prospectus supplement
- 4 Jun 21 424B3 Prospectus supplement
- 3 Jun 21 EFFECT Notice of effectiveness
-
26 May 21 S-3 Shelf registration
ENTO similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in this Registration Statement on Form S-3 of AzurRx BioPharma, Inc. (to be filed on May 26, 2021) of our report dated March 31, 2021, on the consolidated financial statements of AzurRx BioPharma, Inc. as of December 31, 2020 and 2019 and for the years then ended. Our report on the consolidated financial statements of AzurRx BioPharma, Inc. includes an explanatory paragraph about the existence of substantial doubt concerning its ability to continue as a going concern. We also consent to the reference to our Firm under the caption “Experts” in this Form S-3.
/s/ Mazars USA LLP
New York, New York
May 26, 2021